U.S. plans shift of Merck’s COVID-19 treatment to commercial market

  • 📰 globeandmail
  • ⏱ Reading Time:
  • 33 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 16%
  • Publisher: 92%

대한민국 뉴스 뉴스

대한민국 최근 뉴스,대한민국 헤드 라인

Merck said it needs an updated letter of authorization from the U.S. Food and Drug Administration to allow it to start selling the drug commercially

The U.S. government will stop distributing free doses of Merck & Co’s COVID-19 antiviral treatment molnupiravir by the middle of next month and expects it to be sold on the commercial market instead.

Merck, which developed the drug with Ridgeback Biotherapeutics, said in an e-mailed statement on Wednesday that it needs an updated letter of authorization from the U.S. Food and Drug Administration to allow it to start selling the drug commercially. It has taken a back seat to Paxlovid in the United States and the EU regulator recommended against the Merck drug’s use in the region.

It has also been linked to potentially transmissible mutations in the COVID-19 virus, according to a study published in the journal Nature last month. Merck said the study was limited and that it is confident in the clinical profile of the drug.

이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오:

 /  🏆 5. in KR
 

귀하의 의견에 감사드립니다. 귀하의 의견은 검토 후 게시됩니다.

대한민국 최근 뉴스, 대한민국 헤드 라인

Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.

US plans shift of Merck COVID treatment to commercial marketBy Michael Erman (Reuters) - The U.S. government will stop distributing free doses of Merck & Co's COVID-19 antiviral treatment molnupiravir by the ...
출처: SaltWire Network - 🏆 45. / 63 더 많은 것을 읽으십시오 »